Paradigm chief Paul Rennie on IPPS blockbuster potential, 50% phase three milestone
Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Paradigm Biopharma (ASX:PAR) founder and managing director Paul Rennie